DocumentsDate added
Original research
Singh Ahi Rajinderjit1,*,Kaur Virdi Baljeet2.
Affiliation:-
1Associate Professor,2Assistant Professor, Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
The name of the department(s) and institution(s) to which the work should be attributed:
Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
*Corresponding author:-
Dr. Rajinderjit Singh Ahi.
Associate Professor,
Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
Core idea:
The present study is conducted on the diagnosed cases of diabetes to access the Glycated hemoglobin levels and to study the efficacy of oral hypoglycemic agents(OHA) Sulfonyl urea and thiazolidinediones in lowering the levels of blood glucose, Glycated hemoglobin and serum insulin.It was concluded from this study that the oral hypoglycemic agents sulfonyl urea and thiazolidinediones are effective in increasing the sensitivity of cells to insulin and finally decreasing the levels of blood glucose ,Glycated hemoglobin and serum albumin.
Abstract:
Background: Glycated hemoglobin (GHb) test is a reliable indicator of glycemic control and serves as an excellent indicator of the risk for developing long term complications in diabetes mellitus (DM).
Aims: To assess the glycemic control and the efficacy of oral hypoglycemic agents (OHA) in uncontrolled type 2 DM.
Materials and Methods: 60 cases of type 2 DM reporting to Adesh Institute of Medical Sciences and Research, Bathinda, Punjab (India) were divided into 2 groups of 30 patients each (group I: controlled type 2 DM, FBG <126 mg/dl and group II: uncontrolled type 2 DM, FBG >126 mg/dl). In each case, GHb, FBG and serum insulin were estimated. Group II patients were put on OHA for 12 weeks. The parameters were rechecked and compared with baseline.
Statistical analysis: Done with Epi-Info version 6.
Results: The mean FBG levels in group I and II were 116 ± 4.15 mg/dl and 183 ± 25.86 mg/dl, GHb levels were 5.84 ± 0.87% and 11.48 ± 1.59%, while serum insulin levels were 12.15 ± 5.69 µIU/ml and 54.77 ± 13.8 µIU/ml respectively (in each case, p<0.001). In group II patients, following modified treatment for 12 weeks, values declined to 119± 5.66 mg/dl for FBG (35.2% reduction), 6.81 ± 0.63% for GHb (44.3% reduction) and 21.2 ± 5.52 µIU/ml for serum insulin (56.4% reduction) (in each case, p< 0.01).
Conclusions: GHb and fasting serum insulin levels decrease with modified treatment regime especially by addition of insulin sensitizers so that insulin resistance is lowered and better glycemic control is achieved.
Keywords: Diabetes mellitus; oral hypoglycemic agents; glycated hemoglobin; glucose; insulin.
Article citation:
Rajinderjit Singh Ahi,Baljeet Kaur Virdi. Improved glycemic control and lowered insulin resistance by the use of insulin sensitizers in patients with uncontrolled type 2 diabetes mellitus. J Pharm Biomed Sci 2014; 04(02): 67-71. Available at www.jpbms.info.
REFERENCES
1.King H, Aubert RE, Herman WH. Global burden of diabetes: 1995-2025. Diabetes Care 1998; 21(9): 1414-1431.
2.Gonen B. Glycosylated hemoglobin. Diabetologia 1978; 15 (1): 1-8.
3.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications of insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
4.Powers AC. Diabetes Mellitus. Harrison’s Principles of Internal Medicine. 16th edn. Boston, McGraw Hill Medical Publishing, 2005; pp: 2152-2158.
5.Peterson CM, Jones RL, Koeing RJ, Melnin ET, Lehrman MZ. Reversible haematalogic sequelae of diabetes mellitus. Ann Intern Med 1977; 86: 425-429.
6.Nathan DM, Singer DE, Hursthal K, Goodson JD. The clinical information value of glycosylated hemoglobin assay. N Eng J Med 1984; 310: 341-346.
7.Marsh WH, Fingerhut B, Miller H. Determination of blood urea. Clin Chem 1965; 11: 624- 7.
8.Brod J, Sirota JH. Renal clearance of endogenous creatinine in man. Clin Invest 1948; 27: 646.
9.Asatoor AM, King EJ. Simplified colorimetric blood sugar method. Biochem J (Proceeding of the Biochemical Society). 1954; 65: xliv.
10.Frier BM, Ashby JP, Nairn IM, Bairs JD. Plasma insulin, C-peptide and glucagon concentrations in patients with insulin-independent diabetes treated with chlorpropamide. Diab Metab 1981; 7(1): 45-9.
11.Kumar S, Boulton AJM, Nielsen HB, Berthezene F, Muggeo M, Persson B et al. Triglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
12.Miyazaki Y, Ferrannini E, Mahankali A, Cusi K, Mastuda M, Mandarino et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
13.Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of 30 week randomized, double-blind, placebo controlled, parallel group study. Clin Ther 2005; 27(10): 1535-1547.
14.Yamasaki Y, Kawamori R, Wasada T. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Tohoku J Exp Med 1997; 183: 173-183.
15.Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J et al. Liraglutide, a long-acting human glucagon like peptide 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes. Diabetes Care 2007; 30(6): 1608-1610.
16.Iozzo P, Solin O, Hallsten K, Lonnqvist F, Oikonen V, Ferrannini E et al. Effects of metformin and rosiglitazone: monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetic. Diabeties Care 2003; 26: 2069-2074.
17.Derosa G, Cicera AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double blind, randomized, controlled parallel group trial. Clin Ther 2004; 26(5): 744-754.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: None.
Copyright © 2014 Rajinderjit Singh Ahi,Baljeet Kaur Virdi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
Thalquotra Mohit 1,*, Pandey Rajesh2, Singh Jasbir2, Agrawal B.K.3, Sodhi K.S.2
Affiliation:-
1P.G. student, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
2Professor, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
3Professor, Department of Medicine, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1. Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
2. Department of Medicine, MMIMSR, Mullana, Ambala, Haryana, India
*To whom it corresponds:-
Mohit Thalquotra.
P.G. student, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana,India
Mobile:+91-8221033642+91-8221033642
Abstract
Context: Chronic kidney disease (CKD) is a worldwide health problem with an increasing incidence and prevalence. Abnormalities in the structure and function of the thyroid gland and in the metabolism and plasma concentration of thyroid hormones are common in patients with CKD.
Aims: In view of variability of thyroid function tests reported in patients with CKD in previous studies, a prospective study of thyroid profile was performed in patients with CKD.
Setting and design: Prospective cross sectional study in rural setting of Haryana.
Materials and Methods: Total number of 30 patients with CKD on conservative management who were admitted to Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala during the period January 2013-January 2014 were selected in this prospective study. There were two groups (30 patients and 30 controls). Serum T3, T4 and TSH were evaluated in the subjects of both the groups and compared.
Statistical analysis: By SPSS version 12 [SPSS v12 (SPSS Inc., Chicago, IL)].
Results: 23.33% of the uremic patients kept on conservative treatment or on regular hemodialysis showed significant reduction of serum T3 and T4 in comparison to the control group. However, the level of TSH did not show significant alterations.
Conclusions: Thyroid dysfunction merits attention for the better management of CKD patients.
Keywords: Chronic kidney disease, Hemodialysis, Triiodothyronine (T3), Thyroxine (T4), Thyroid stimulating hormone (TSH).
REFERENCES
1.Choi AL, Rodriguer RA,Bacchetti P, Bertenthal D, Hernander GD, O’Hare AM. White/ Black racial differences in risk of end stage disease and death. Am J Med 2009: 122:672-78.
2.Aggarwal SK,Dash SC, Irshad M. Prevalence of chronic kidney failure in adults in Delhi, India. Nephrol Dial Transplant 2005; 20:1638-1642.
3.Mani MK. Prevention of chronic kidney failure at the community level. Kidney Int 2003; 63(Suppl 83):S86–S89.
4.Bargman JM,Skorecki K. Chronic kidney disease. In: Fauci AS, Kasper DL, Longo DL, Lascalzo J, Braunwald E, Hauser Sl, Jamson JL, editors. Harrison’s Principles of Internal Medicine, 17th ed: vol. 2: McGraw Hill; London ;2008.pp.1761-1771.
5.Kaptein EM,Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriquez HJ, et al. The thyroid in end stage kidney disease. Medicine (Baltimore) 1988; 67: 187-97.
6.Bargman JM,SKorecki K. Chronic kidney disease. In: Longo DL, Fauci AS, Kasper DL. Harrison’s Principles of Internal Medicine, Vol. 2, 18th edn., 2011; McGraw Hill, London, pp. 2289-2313.
7.Weissel M,Stummvoll HK, Kolbe H, Höfer R. Basal and TRH stimulated thyroid and pituitary hormones in various degree of kidney insufficiency. Acta Endocrinol 1979; 90: 23-32.
8.Jain R, Isaac RM, Gottschalk ME. Transient central hypothyroidism as a cause of failure to thrive in newborns and infants. J Endocrinol Invest 1994; 17:631-637.
9.Webster D. Autozyme urea reagent set of determination of urea/blood urea nitrogen based on enzymatic method using urease. Clin Chem 1977; 23:663.
10.Bowers LD,Wong ET. Kinetic serum creatinine assays. II. A critical evaluation and review. Clin Chem 1980; 26: 555–561.
11.Kaptein EM.Thyroid hormone metabolism and thyroid diseases in chronic kidney failure. Endocr Rev 1996; 17: 45–63.
12.Czernichow P, Dauzet MC, Broyer M, Rappaport R. Abnormal TSH, PRL and GH response to TSH releasing factor in chronic kidney failure. J Clin Endocrinol Metab 1976; 43: 630–637.
13.Spaulding SW, Gregerman RI. Free thyroxine in serum by equilibrium dialysis: Effects of dilution, specific ions and inhibitors of binding. J Clin Endocrinol Metab 1972;34: 974–982.
14.Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: A new facet of inflammation in end-stage kidney disease. J Am Soc Nephrol 2005;16: 2789–2795.
15.Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007; 262: 690–701.
16.Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1190-1197.
17.Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H, et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 2011; 33: 25-32.
18.Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, et al. Low triiodothyronine and cardiomyopathy in patients with end-stage kidney disease. J Hypertens 2006; 24: 2039-2046.
19.Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage kidney disease. Kidney Int 2006; 70: 523–528.
20.Song SH,Kwak S, Lee DW, Kang YH, Seong EY, Park JS et al . The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant 2009; 24:1534–1538.
21.Avasthi G,Malhotra S, Narang APS, Sengupta S. Study of thyroid functions in patients of chronic kidney failure. Indian J Nephrol 2001; 11: 165-170.
22.La Franchi S.Thyroid functions in children with kidney failure. J Pediatr 1991; 118: 896-8.
23.Ramírez G,Jubiz W, Gutch CF, Bloomer HA, Siegler R, Kolff WJ et al. Thyroid abnormalities in kidney failure. A study of 53 patients on chronic dialysis. Ann Internal Medicine 1973; 79: 500-4.
24.Dudani RA,Desai KB, Mehta MN, Mani LS, Acharya VN. Thyroid dysfunction in uraemia. J Assoc Physicians India 1981; 29: 1037-40.
25.Karunanidhi A,Kanagasabapathy AS, Shastry JC, Koshy TS. Thyroid function in patients with chronic kidney failure. Indian J Med Res 1979; 69: 792-7.
26.Quion-verde H.Prevalence of thyroid disease in chronic kidney failure and dialysis patients. IXth Int Congr of Nephrol, 1984; 120.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Article citation:
Thalquotra Mohit ,Pandey Rajesh, Singh Jasbir, Agrawal B. K., Sodhi K.S. Evaluation of thyroid profile in patients with chronic kidney disease. J Pharm Biomed Sci 2014; 04(02): 143-147. Available at www.jpbms.info.
Copyright © 2014 Thalquotra Mohit, Pandey Rajesh, Singh Jasbir, Agrawal B. K., Sodhi K.S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Panjiyar K.Shambhu1,*,Kumari A.R2,Jayaram Subha3,Pandey Rajesh4,Singh Jasbir4
Affiliation:-
1Lecturer, Department of Biochemistry, Kantipur Dental College, Kathmandu, Nepal
2Professor, 3Assistant Professor, Department of Biochemistry, PES Medical College, Kuppam, Andhra Pradesh, India
4Professor, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1. Department of Biochemistry, Kantipur Dental College, Kathmandu, Nepal.
2. Department of Biochemistry, PES Medical College, Kuppam, Andhra Pradesh,India
3. Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana,India
*Corresponding author:-
Shambhu K. Panjiyar.
Lecturer, Department of Biochemistry, Kantipur Dental College, Kathmandu, Nepal
Mobile: 00977-9841155094
Abstract:
Context: Chronic kidney disease (CKD) is an increasing health problem worldwide. The status of trace elements in CKD, though altered, is often unexplored.
Aim: To evaluate serum zinc, copper and magnesium in CKD patients, before and after hemodialysis (HD).
Setting and design: Community-based prospective cross-sectional study in rural setting of Andhra Pradesh.
Materials and methods: 30 cases diagnosed as CKD patients undergoing HD, and 30 healthy subjects as controls were selected. The cases were further divided into 2 groups namely pre-HD and post-HD. In each subject, serum zinc, copper and magnesium were analyzed.
Statistical analysis: It was done by entering the data in SPSS version 12 [SPSS v12 (SPSS Inc, Chicago, IL)]. Bar charts and tables were prepared in Microsoft excel 2007 software program.
Results: Serum zinc levels are decreased in CKD, however, the pre-HD and post-HD values were not significantly different. Serum copper levels were unaltered. Finally, serum magnesium levels were increased in CKD but decreased significantly following HD.
Conclusions: Alteration in trace elements may occur in CKD, and may be further modified by HD. This aspect requires attention and rectification where necessary.
Keywords: Chronic kidney disease; copper; hemodialysis; magnesium; trace elements; zinc.
Panjiyar K.Shambhu,Kumari A.R,Jayaram Subha,Pandey Rajesh,Singh Jasbir. Evaluation of serum zinc, copper and magnesium in patients with chronic kidney disease, before and after hemodialysis. J Pharm Biomed Sci 2014; 04(02): 88-91. Available at www.jpbms.info.
REFERENCES
1.Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al., Chronic kidney disease: global dimension and perspectives, Lancet 382 (2013) 260-72.
2.McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, et al., Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program, Am J. Kidney Dis. 57 (2011) S24-31.
3.van Blijderveen JC, Straus SM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme K, A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands, Int Urol Nephrology (2013) (Epup ahead of print; PMID: 24072454).
4.Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, et al, Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease), BMC Nephrol.14 (2013) 114.
5.Maruma F, Nakamura M, Sato M ,Shimada B, Tsukamato S, Iwanami S, Deranged C, Al and Mg content in the tissues of patients with chronic renal failure as measured by non destructive neutron ouctruation analysis, Int. J. Artif. Org. 8 (1985) 319-324.
6.Tsutsumi R, Ohashi K, Tsutsumi YM, Horikawa YT, Minakuchi J, Minami S, et al, Albumin-normalized serum zinc: a clinically useful parameter for detecting taste impairment in patients undergoing dialysis, Nutr. Res. 34 (2014) 11-16.
7.Utas C, Kilic M, Cucer N, Dusunsel R, Saraymen R, et al, Comparision of the plasma trace elements levels in patients with chronic renal failure before and after haemdialysis and healthy subjects, Gazi. J. Med. 3 (1993) 125-127.
8.Webseter D, The immediate reaction between bromcresol green and serum as a measure of albumin content, Clin. Chem. 23 (1977) 663-5.
9.Bowers LD, Kinetic serum creatinine assays I. The role of various factors in determining specificity, Clin. Chem. 5 (1980) 551-4.
10.Basils M.E., Uric acid metabolism in man, Adv. Clin. Chem.18 (1976) 213.
11.Makino T, Saito M, Horiguchi D, Kina K, A highly sensitive colorimetric determination of serum zinc using water-soluble pyridylazo dye, Clin. Chim. Acta 1 (1982) 127-35.
12.Abe A, Yamashita S, Noma A, Sensitive, direct colorimetric assay for copper in serum, Clin. Chem. 4 (1989) 552-4.
13.Wills MR, Sunderman FW, Savory J, Methods for the estimation of serum magnesium in clinical laboratories, Magnesium 5 (1986) 317-27.
14.Dvornik S, Cuk M, Racki S, Zaputovic L, Serum trace concentrations in the maintenance hemodialysis patients, Coll. Antropol. 30 (2S006)125-129.
15.Nicholas A, Boon NR, Hunter JAA, Major manifestations of renal and urinary tract disease. Davidson’s principles and practice of medicine, Division of Reed Elsevier India Pvt. Ltd., New Delhi, 2002, chapter 14, pp 585-603.
16.Skoreki K, Green J, Brenner BM, Chronic renal failure. Harrison’s principles of internal medicine, 15th edition, Mc Graw Hill, New York, 2001, chapter 270, pp 1551-72.
17.Paydas S, Albayrak A, Yureger G, Saglikes Y, Trace element in haemodialysis. Proceedings of the third international congress on trace elements in health and disease, Adana (Turkey), March 31- April 8, 1989, pp 615-618.
18.Hosokawa S. Nishitani H, Tomila K, Tomoyoshi T, NishioT ,Sawanishi K, et al, Serum copper concentration changens in chronic haemodialyzed patients, Uremia Invest. 9 (1985) 63-67.
19.Sondheimer JH, Mahajan KS, Rye DL, Hamdan BKA, Migdal SD, Prasad A, et al, Elevated plasma copper in chronic renal failure, Am. J. Clin. Nutr. 47 (1988) 869.
20.Ghoreshi Z, Ahaley SK, Rasooli I, Effect of Hemodialysis on trace elements in patients with acute and chronic renal failure, J. Medi. Islam 14 (2001) 329-331.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: None
Copyright © 2014 Panjiyar K.Shambhu,Kumari A.R,Jayaram Subha,Pandey Rajesh,Singh Jasbir. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
HG Hamza1,*, A I Saleh1, Z K Mohammed1, H A Ngadda2
Affiliation:-
1Department of Biochemistry, Faculty of Science, University of Maiduguri. PMB 1069, Maiduguri, Nigeria
2Department of Histopathology, College of Medical Sciences, University of Maiduguri. PMB 1069, Maiduguri, Nigeria
The name of the department(s) and institution(s) to which the work should be attributed:
University of Maiduguri. PMB 1069, Maiduguri, Nigeria
*Corresponding author:
Dr HG Hamza.
Department of Biochemistry. Faculty of Science University of Maiduguri, PMB 1069 Nigeria
Abstract:
The present study aims at investigating the chemopreventive potentials of water extract of traditional medicinal plant, Detarium microcarpum against mycotoxin induced hepatic and renal damage in rats. The result of the study revealed that the mycotoxin ingested animal showed drastic weight loss, induced liver and kidney damage through elevating marker enzymes and serological variables. However, administration of 750 mg/kg body weight of the water extract of Detarium microcarpum effectively ameliorated the deviation caused by liver and kidney damage in response to mycotoxin ingestion. Pathological examination of the liver and kidney tissues also supported the biochemical findings. From the current investigation it can be concluded that supplementation of plant extract was beneficial in modulating the alteration induced in liver, kidney and serum variables of rats under the effect of mycotoxin.
Keywords: Mycotoxins; Deterium microcarpum; Chemopreventive potentials.
HG Hamza, A I Saleh, Z K Mohammed, H A Ngadda. Effect of aqueous extract of detarium microcarpum (Guill&Sperr) on mycotoxin- induced tissue damage in albino rats. J Pharm Biomed Sci 2014; 04(02): 92-99. Available at www.jpbms.info.
REFERENCES
1.Boudra, H. and Morgavi, L..fungal secondary metabolites from Monascus spp reduce rumen methane production in vitro and in vivo. J. Animal Sc. 2011;94 (11): 5611-9.
2.Chapatwala, K.D., Boykin, M.A. and Rajanna, B.. Effects of intraperitonealy injected cadmium on renal and hepatic glycogenic enzymes in rats. Drug chem. Toxicol. 1982; 5:305-317.
3.Chawla, R. (1999). Serum total protein and albumin-globulin ratio. In: Practical Clinical Biochemistry Method and interpretations (eds Chawla R). Jaypee Brothers Medical Publishers, New Delhi, India. pp.106-118.
4.Chibundu, N. E., Adegboyega, C. O. and Stephen, O. Fapohunda. Zearalenone Production by Naturally Occurring Fusarium Species on Maize, Wheat and Soybeans from Nigeria J. Biol. Environ. Sci., 2008; 2(6), 77-827.
5.Cortbett, J. V.. Renal Function Tests In: Laboratory Tests and Diagnostic Procedures. 5th ed. Prentice Hall Health: 90-107.
6.Dobbs, N.A., Twelves, C.J., Gregory, W., Cruickshanka, C., Richards, M.A. and Rubens, R.D. Epirubicin in patients with liver dysfunction. Development and evaluation of a novel dose modification scheme. Eur. J. Cancer. 2003; 39: 580-586.
7.Daumass, B.T., Watson, W.A. and Biggs, H.G. Albumin standards and the measurements of serum albumin with Bromocresol green. Acta. 1971; 31:87-96.
8.Ebi, G.C and Afieroho O.E. Phytochemical Analysis and Antimicrobial studies on D. Microcarpum (Guill and Sperr) Seeds. Afr.J. Biotech. 2011; 10457-462.
9.Falodun A., Okunrobo L.O. and Uzoamaka N. Phytochemical screening and anti-inflammatory evaluation of methanolic and aqueous extracts of Euphorbia heterophylla Linn. Afr. J. Biotech. 2006; 5: 529-532.
10.Farombi, E.O. , Adepoju BF., Ola-Davis OF., Emerole GO.Prevention of Aflatoxin B1 induced genotoxicity and hepatic oxidative damage in rats by kolaviron: A natural bioflavonoids of Garcinia kolaseeds Eur.J.Cancer Prev. 2005;14(3):207-214.
11.Galati ,E.M., Mondello, M.R., Lauriano ,E.R., Taviano M.F., Galluzo, M., and Miceli ,N. Opuntia ficus indica (L) Mill fruit juice protects liver against carbon tetrachloride induced liver injury. Phytother. Rev. 2005;19: 796-800.
12.Gupta R., Sharma V., Sharma S. Chemopreventive potential of Tinospora cordiofolia root extract against Aflatoxin B1 induced toxicity in swiss Albino mice Int.J Biol.Med.Res. 2011; 2(4):1115-1121.
13.Hamza-Idris, H., Buratai, L.T., Geidam,M.A. , Magaji, M.A., Saleh,S.A., Kunaba, A. Effect of Aqueous Extract of Detarium Microcarpum (Guill andsperr) Stem Bark on Benzidine Induced Liver Damage in Albino Rats. Nig J. Exp and Appl. Biol. 2012;13(1)61-64.
14.Hamza-Idris H and Oyeanusi S. In vitro Evaluation of Stembark Extract of Deterium microcarpum (Guill&Sperr) for Antimicrobial Activity.Nig. J. Exp and App. Biol. 2012;13(1)55-59.
15.Janquera, L.C. and Carneiro, J. (2005). Basic Histology ; test and atlas. 11th ed. Mc Graw-Hill Pp1-3.
16.Kaplan L.A., Szabo, L.L.and Opherin ,E.K, (1988).Clin. Che.: Interpretations and techniques.3rd ed. Lea and Feblinger, Philadelphia Klein, B., Read, P.A. and Babson, L.A. (1960) Colorimetric method for determination of alkaline phosphatase. Clin Chem. 6: 269-952.
17.Kew ML. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000; 335: 951-952.
18.Liebert JJ, Matlawska I, Bylka W, Murias M. Protective effects of Aquilegia vulgaris L. on aflatoxin B1-induced hepatic damage in rats. Environ. Toxicol. Pharmacol. 2006; 22: 58-63.
19.Mohamed AM, Metwally NS. Antiaflatoxigenic activities of some plant aqueous extracts against aflatoxin B1- induced renal and cardiac damage. J. Pharmacol.2009; Toxicol. 4: 1-16
20.Singh RP, Banerjee S, Kumar PVS, Raveesha KA, Rao AR. Tinospora cordifolia induces enzymes carcinogen/drug metabolism and antioxidant system, and inhibit lipid peroxidation in mice. Phytomed.2006; 13: 78-84.
21.Soladoye, M.O. and O.O. Oyesiku,(2008). Taxonomy of Nigerian Medicinal Plant: A Text Book of Nigerian Medicinal Plant. 1st Edn., University of Lagos Press, Lagos, Nigeria, pp: 93.
22.Upadhyay, R., N.D. Pandey, S.S. Narvis, A. Verma and B. Ahmed. Antihepatotoxic effects of Fermini lemonia fruit against carbon tetrachloride induced hepatic damage in albino rats. Chin. Med. 2010; 1: 1.
23.Williamson, J.A., Bosher, J.M., Skinner, A., Sheer, D., Williams, T. and Hurst, H.C. Chromosomal mapping of the human and mousehomologues of two new members of the AP-2 family of transcription factors. Genomics. 1996; 35: 262-264.
24.Klein B, Read, PA and Babson CA. Calorimetric method for determination of alkaline phosphatase. Clin. Chem.1960; 6, 269-295.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: None
Copyright © 2014 HG Hamza, A I Saleh, Z K Mohammed, H A Ngadda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
Khetri R1, Dugar D2,*, Ghata S3
Affiliation:-
1Associate professor, 2Assistant professor, 3 2nd year P.G Student, Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.
The name of the department(s) and institution(s) to which the work should be attributed:
Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
*To whom it corresponds:-
Dr. DHARMENDRA DUGAR M.S.
Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Contact no:- +91-9437091846+91-9437091846
Abstract
Background: Inguinal hernia repair is one of the most commonly performed general surgical procedures in practice. The introduction of a laparoscopic technique has sparked a debate in the literature over the superiority of this method versus open repair. In this article, we examine the advantages and disadvantages of these two approaches in inguinal hernia repair.
Material & method: We conducted a prospective interventional type of hospital based study of 40 patients with inguinal hernia. Out of this 20 patients underwent laparoscopic repair (TEP) and the rest had open hernia repair. Patients were selected considering the inclusion and exclusion criteria. Factors studied were operative time, post-op pain and complications comparing both procedures. Follow-up was done for 2 years.
Result: Laparoscopic hernia repair compared to open method takes more operative time [79min/61min], less painful [1.5/3 in visual analogue], less hospital stay [3days/8days] respectively. There was no major complication in both the procedure and no recurrence in 2 years of follow-up.
Conclusion: Laparoscopic hernia repair is superior to open hernia repair in respect to post-operative pain, ambulation and easy return to work in experienced hands. Laparoscopy is safe with complication rate same as open hernia repair performed by a surgeon experienced in laparoscopic technique.
Key words: Laparoscopy, Totally-Extraperitoneal, Transabdominal-Preperitonealdfgj.
REFERENCES
1.McCormack K, Scott NW, Go PM, Ross S, Grant AM; Laparoscopic techniques versus open techniques for inguinal hernia repair,Cochrane Database Syst Rev. 2003;(1):CD001785.
2.Stoker DL, Speilgalhalter DJ, Singh R, Wellwood JM. Laparoscopic versus open hernia repair: randomized prospective trial. Lancet 1994; 343 : 1243-5.
3.Millikan KW, Koisik ML, Doolas A. A prospective comparison of transabdominal preperitoneal laparoscopic hernia repair versus traditional open hernia repair in a university setting. SurgLaproscEndosc 1994; 4: 247-53.
4.WilsonMS, Deans GT,mBrough WA. Prospective trial comparing Lichenstein with Laparoscopic tension free mesh repair of inguinal hernia. Br J Sur 1995; 82: 274-7
5.Dunn DC, Wijesinghe LD, Pollard SG, Collire DSTJ. Prospective rehabilitation following laparoscopic hernia repair. Minimally invasive therapy 1994;3:159
6.Neumayer L, GiobbeHurder A, Johansson O, et al. Open mesh versus laparoscopic mesh repair of inguinal hernia. N Eng J Med 2004; 350 : 1819-1827
7.MRC Laparoscopic groin hernia trial group. Laparoscopic versus open hernia repair of groin hernia. A randomized comparison. Lancet 1999; 354 : 185-190.
8.Stoker DL, Spegelhalter DJ, Singh R, et al. Laparoscopic versus open inguinal hernia repair, randomiz.d prospective trial. Lancet 1994; 343 : 1243-1245.
9.Felix E, Crafton B, Scott S, Geis P, Duncan T, Sewell R, et al. Causes of recurrence after laparoscopic hernioplasty. A multicenter study. SurgEndosc 1998; 12: 226- 31.
10.Ferzli GS, Frezza EE, Pecoraro AM Jr, Ahren KD. Prospective randomized study of stapled versus unstapled mesh in a laparoscopic pre peritoneal inguinal hernia repair. J Am CollSurg 1999; 188 : 461-5
11.MRC, Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicenter randomized clinical trial. Br J Surg, 2001; 88(5):653-61.
Article citation:
Khetri R, Dugar D, Ghata S. Comparative Study of Open Versus Laparoscopic Inguinal Hernia Repair. J Pharm Biomed Sci. 2014; 04(02): 113-117. Available at www.jpbms.info
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Abbreviations: Laparoscopy: Lap; Totally-Extraperitoneal: TEP; Transabdominal-Preperitoneal:TAPP.
Copyright © 2014 Khetri R, Dugar D, Ghata S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.